Corbus Pharmaceuticals Holdings (CRBP) Operating Income (2013 - 2025)

Corbus Pharmaceuticals Holdings' Operating Income history runs 13 years deep, the most recent figure standing at $1.1 million for Q3 2025.

• In Q3 2025, Operating Income fell 40.88% year-over-year to $1.1 million; the TTM figure through Sep 2025 stood at -$36.0 million (down 546.37% YoY), while the FY2024 annual figure was $6.3 million, up 114.0% from the prior year.
• Operating Income was $1.1 million for Q3 2025 at Corbus Pharmaceuticals Holdings, up from -$19.2 million in the prior quarter.
• In the past five years, Operating Income ranged from a high of $1.9 million in Q3 2024 to a low of -$19.8 million in Q1 2025.
• Historically, Operating Income has averaged -$9.1 million across 5 years, with a median of -$10.0 million in 2021.
• The sharpest annual moves came in 2024 and 2025: Operating Income soared 120.06% in 2024, then sank 2023.64% in 2025.
• A 5-year view of Operating Income shows it stood at -$10.0 million in 2021, then retreated by 7.99% to -$10.8 million in 2022, then gained by 6.42% to -$10.1 million in 2023, then surged by 117.62% to $1.8 million in 2024, then plunged by 36.8% to $1.1 million in 2025.
• The last three Operating Income figures came in at $1.1 million (Q3 2025), -$19.2 million (Q2 2025), and -$19.8 million (Q1 2025), per Business Quant data.